- Trial phase
- Phase 2
- Time to market
- At least 3-5 years if successful, Phase 3 trials have not yet started for any indication.
- Why 5/10
- Ifetroban is mid-stage (Phase 2) across all indications with no hard-dated binary catalyst in the next ~12 months. The next major event, an FDA Type B meeting to design a Phase 3 trial for DMD cardiomyopathy, has been announced as a goal but not yet scheduled. The asset-sale transformation (completed June 2026) was the recent major catalyst; the stock has already re-rated from ~$3.75 to ~$6.00. Impact is moderate (5) because ifetroban is now the company's sole asset, but no dated binary is imminent.
Cumberland is now a pure-play ifetroban development company with ~$100M+ cash post the Apotex sale. The key swing factor is when and how management engages the FDA on a Phase 3 pathway for DMD cardiomyopathy, watch for an FDA meeting announcement or a specific Phase 3 timeline. The stock remains highly speculative with thin liquidity and a mixed analyst consensus (3 Hold, 1 Sell, 2 Strong Sell).
Price Chart
Executive Summary
Ifetroban is an oral drug originally discovered by Bristol-Myers Squibb, now owned and developed by Cumberland Pharmaceuticals (CPIX). It targets the thromboxane receptor to fight inflammation and fibrosis in rare diseases. In February 2025, positive Phase 2 data showed it improved heart function in Duchenne muscular dystrophy (DMD) patients, the leading cause of death in DMD. The drug has FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations for DMD cardiomyopathy. Cumberland recently sold its entire commercial product portfolio to Apotex for $100M (closed June 2026) and is now a pure-play development-stage biotech focused entirely on ifetroban across DMD, systemic sclerosis, and idiopathic pulmonary fibrosis. With no PDUFA date set and Phase 3 not yet begun, the stock trades on pipeline narrative and regulatory-pathway catalysts rather than near-term approval.
How It Works
Ifetroban blocks a specific receptor (the thromboxane receptor) on cells that, when overactivated, drives inflammation, tissue scarring (fibrosis), and blood vessel constriction. By blocking this receptor, the drug aims to prevent or slow damage to the heart and lungs in rare diseases where these processes are out of control.
Trial Status
Positive Phase 2 top-line results announced Feb 2025 for DMD cardiomyopathy (FIGHT DMD trial). Phase 2 trials are also recruiting in systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF, FIGHTING FIBROSIS trial). The DMD program has an ongoing open-label extension. Management plans to discuss a pivotal trial path with the FDA for DMD.
The Two-Sided Case
Upcoming Catalysts
- FDA Type B meeting to discuss Phase 3 pivotal trial design for DMD cardiomyopathy (management stated goal, no specific date yet)
- Phase 2 FIGHTING FIBROSIS trial for IPF, topline readout (recruiting; no estimated primary completion date published)
- Phase 2 systemic sclerosis trial, interim or final data (ongoing; NCT02682511)
- Open-label extension data updates from FIGHT DMD trial, could be presented at medical conferences
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Cumberland Pharmaceuticals Inc. Press Release CPIX ·Originating report